Early results from a biomarker-directed phase 2 trial of SY-1425 in combination with azacitidine or daratumumab in non-APL acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) Meeting Abstract
| Authors: | Cook, R. J.; Moyo, T.; Liesveld, J. L.; Rizzieri, D. A.; Stein, E. M.; De Botton, S.; Roboz, G. J.; Sekeres, M. A.; Jurcic, J. G.; Raza, A.; Redner, R. L.; Bixby, D. L.; Cortes, J. E.; Stephens, K.; Volkert, A.; Kang, Q.; Di Tomaso, E.; Roth, D. A.; Vigil, C. E. |
| Abstract Title: | Early results from a biomarker-directed phase 2 trial of SY-1425 in combination with azacitidine or daratumumab in non-APL acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-29 |
| Language: | English |
| ACCESSION: | WOS:000454837607341 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood-2018-99-111285 |
| Notes: | Meeting Abstract: 2735 -- Source: Wos |
